Literature DB >> 11309305

Partial deletions of the long and short arm of chromosome 3 point to two tumor suppressor genes in uveal melanoma.

F Tschentscher1, G Prescher, D E Horsman, V A White, H Rieder, G Anastassiou, H Schilling, N Bornfeld, K U Bartz-Schmidt, B Horsthemke, D R Lohmann, M Zeschnigk.   

Abstract

Uveal melanoma is the most common form of primary eye cancer. Monosomy 3, which is an unusual finding in tumors but is present in approximately 50% of uveal melanomas, is significantly correlated with metastatic disease. To obtain positional information on putative tumor suppressor genes on this chromosome, we have investigated tumors from 333 patients by comparative genomic hybridization, microsatellite analysis, or conventional karyotype analysis. A partial deletion of the long arm was found in eight tumors, and the smallest region of deletion overlap (SRO) spans 3q24-q26. We found six tumors with a partial deletion of the short arm and were able to define a second SRO of about 2.5 Mb in 3p25. This SRO does not overlap with the VHL gene. Our finding suggests a role for two tumor suppressor genes in metastasizing uveal melanoma and may explain the loss of an entire chromosome 3 in these tumors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11309305

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  19 in total

1.  Frequency, molecular pathology and potential clinical significance of partial chromosome 3 aberrations in uveal melanoma.

Authors:  Mohamed H Abdel-Rahman; Benjamin N Christopher; Mohammed F Faramawi; Khaled Said-Ahmed; Carol Cole; Andrew McFaddin; Abhik Ray-Chaudhury; Nyla Heerema; Frederick H Davidorf
Journal:  Mod Pathol       Date:  2011-04-15       Impact factor: 7.842

Review 2.  The genetics of uveal melanoma: an emerging framework for targeted therapy.

Authors:  J William Harbour
Journal:  Pigment Cell Melanoma Res       Date:  2012-02-13       Impact factor: 4.693

Review 3.  Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma.

Authors:  Ying-Wen Su; Ming-Chih Chang; Ming-Fu Chiang; Ruey-Kuen Hsieh
Journal:  J Neurooncol       Date:  2005-02       Impact factor: 4.130

4.  Mechanisms of resistance to imatinib mesylate in KIT-positive metastatic uveal melanoma.

Authors:  Armelle Calipel; Solange Landreville; Arnaud De La Fouchardière; Frédéric Mascarelli; Michel Rivoire; Nicolas Penel; Frédéric Mouriaux
Journal:  Clin Exp Metastasis       Date:  2014-03-21       Impact factor: 5.150

5.  Classification of arrayCGH data using fused SVM.

Authors:  Franck Rapaport; Emmanuel Barillot; Jean-Philippe Vert
Journal:  Bioinformatics       Date:  2008-07-01       Impact factor: 6.937

Review 6.  The biology and management of uveal melanoma.

Authors:  Takami Sato; Fei Han; Akira Yamamoto
Journal:  Curr Oncol Rep       Date:  2008-09       Impact factor: 5.075

Review 7.  [Uveal and iridociliary melanomas in young patients : A retrospective analysis of 57 cases].

Authors:  L J Heyer; C Metz; D Flühs; C M Heyer; N Bornfeld
Journal:  Ophthalmologe       Date:  2016-12       Impact factor: 1.059

8.  Monosomy 3 status of uveal melanoma metastases is associated with rapidly progressive tumors and short survival.

Authors:  Mohamed H Abdel-Rahman; Colleen M Cebulla; Vishal Verma; Benjamin N Christopher; William E Carson; Thomas Olencki; Frederick H Davidorf
Journal:  Exp Eye Res       Date:  2012-05-05       Impact factor: 3.467

9.  Identification of monosomy 3 in choroidal melanoma by chromosome in situ hybridisation.

Authors:  M T Sandinha; M A Farquharson; F Roberts
Journal:  Br J Ophthalmol       Date:  2004-12       Impact factor: 4.638

10.  Comparison of Gene Expression Profiling and Chromosome 3 Analysis by Fluorescent in situ Hybridization and Multiplex Ligation Probe Amplification in Fine-Needle Aspiration Biopsy Specimens of Uveal Melanoma.

Authors:  Michael A Klufas; Elizabeth Richter; Sujit Itty; Christian Moreno; Colin A McCannel; Tara A McCannel
Journal:  Ocul Oncol Pathol       Date:  2017-06-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.